The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:Zacks Suggests Investors Favor BioTetch ETFs Not Rated 0.0 Email Routing List Email & Route  Print Print
Wednesday, June 12, 2013

Zacks Suggests Investors Favor BioTetch ETFs

News summary by MFWire's editors

As the market continues to improve, investors are taking on more risk, which is good news for biotech ETFs, Zacks writes.

Biotech is a high growth sector that is seeing some momentum and performing better than broader health care sector funds. The average outperformance of the biotech ETF sector over the broader health care market has been 800 basis points.

The biotech sector could eventually benefit from Obamacare, as it won't have to deal with taxes regarding medical device space and biotech drugs are likely to be used by a large portion of insured Americans.

Biotech companies are also well positioned as takeover targets as they are small mid cap companies. Zacks suggests Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF [profile] and First Trust Amex Biotechnology Index Fund [profile]. 

Edited by: Casey Quinlan

Stay ahead of the news ... Sign up for our email alerts now

 Do You Recommend This Story?

Return to Top
 News Archives
2021: Q1
2020: Q4Q3Q2Q1
2019: Q4Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Add to My Yahoo!
follow us in feedly

©All rights reserved to InvestmentWires, Inc. 1997-2021
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use